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Abstract: Ricin is a potent cytotoxin easily purified in large quantities. It presents a 
significant public health concern due to its potential use as a bioterrorism agent. For this 
reason, extensive efforts have been underway to develop antidotes against this deadly 
poison. The catalytic A subunit of the heterodimeric toxin has been biochemically and 
structurally well characterized, and is an attractive target for structure-based drug design. 
Aided by computer docking simulations, several ricin toxin A chain (RTA) inhibitors 
have been identified; the most promising leads belonging to the pterin family. To date, 
the most potent RTA inhibitors developed using this approach are only modest inhibitors 
with apparent IC50 values in the 10
-4
 M range, leaving significant room for improvement. 
This thesis discusses the development of a subset of inhibitors belonging to the pterin 
family in which amino acids have been utilized as building blocks. Inhibitors in this 
family have achieved a significant increase in potency, and have provided valuable 
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Chapter 1:  Background 
Ricin, from the castor plant Ricinus communis, is a type II holotoxin belonging to 
the Ribosome Inactivating Protein (RIP) superfamily [1, 2]. Type II RIPs are comprised 
of a catalytic A subunit, and a lectin B subunit which mediates cellular uptake.  For ricin, 
these chains are referred to as RTA and RTB respectively.  Type I RIPs consist of only 
the catalytic domain.  Type I RIPs appear to play a role in plant antiviral defenses; they 
are not cytotoxic unless they can be delivered to the cytoplasm, for example by breaching 
the cell [3].  
Ricin has received significant attention since the infamous umbrella tip 
assassination of Georgi Markov publically demonstrated the extreme lethality of the toxin 
[4, 5]. Due to its ease of extraction in large quantities from castor beans, which are 
processed worldwide on an industrial scale, there is a real threat of ricin being used as a 
biowarfare agent. It is therefore important to develop an antidote for the deadly toxin as a 
defense against such an attack. 
The use of structure based drug design is an attractive approach for the 
development of small molecule inhibitors for the treatment of ricin intoxication. The use 
of X-ray crystallography and/or NMR spectroscopy to obtain structural information 
detailing the interaction between an inhibitor and its target macromolecule is the 
cornerstone of structure based drug design. The X-ray structures of ricin and RTA are 
known [6, 7, 8], and complexes with substrate analogs have revealed key features of the 
RTA active site [9, 10]. When the macromolecular target structure is known, medicinal 
chemists can rationally develop synthetic derivatives of an existing inhibitor to improve 
potency by creating more favorable binding interactions with the target. The work 
2 
 
presented in this thesis focuses on the use of this approach in the development of 




Chapter 2: Ricin Structure and Action 
2.1 – X-ray structure of ricin 
The X-ray structure of the ricin holotoxin was initially solved to 2.8 Å resolution 
[7] and later refined at 2.5 Å [8], allowing the molecular description of the individual 
protein chains [8, 11].  The cloned A chain was later crystallized and solved in two 
different space groups at 2.1 Å resolution [20] and 1.8 Å respectively [12].  The X-ray 
structures allow an analysis of the suitability of each chain as a drug design target. 
2.2 – RTB not suitable for drug design 
RTB would be a sound choice for inhibitor design if small molecules could be 
made that would bind tightly to it and prevent the holotoxin from entering cells.  The 
analysis of the X-ray structure showed that the B chain of ricin is composed of two 
domains, which are each composed of three related subdomains.  Only one subdomain of 
each domain binds galactosides, and these two binding sites are over 50 Å apart (Figure 
1), on opposite ends of the protein [13, 14].   The binding sites individually exhibit only 
weak binding to galactosides [16] with Kd values in the millimolar range. This weak 
binding at each site is biologically tolerable because the two widely separated sites 
contribute independently to the free energy of binding, and because the target cell surface 
is literally covered with galactosides [17].   This is not useful for inhibitor design, 
however.  The RTB galactose binding pockets are small and make only weak interactions 
with galactose [13, 14].  Designing effective ligands to the shallow, polar galactose 
binding sites is difficult [15, 23], and the two sites are also too far apart for a small 




Figure 1: Xray structure of ricin holotoxin (PDB ID: 2AAI). The A chain is shown in 
orange and the B chain is colored blue, with galactoside binding sites shown 
as surfaces. 
2.2 – RTA is a reasonable target for inhibitor design 
Ricin Toxin A chain chemically inactivates the eukaryotic ribosome by hydrolysis 
of a single adenine base (A4324) on the sarcin-ricin loop (SRL) of the 28S rRNA of the 
large subunit [18, 19].  Ricin shows a Km for ribosomes around 1 μM, and a kcat of 
around 1500 min-1, depending on the ribosome species [19, 20, 21].   The catalytic 
efficiency of this hydrolysis reaction, kcat/Km, is near the diffusion limit.  This means 
that ricin has evolved to enzymatic perfection for this specific ribosome inhibiting 
reaction. In contrast, ricin attacks naked RNA at a rate about 104-105 times more slowly 
[19], and only at nonphysiological (acidic) pH [22], suggesting this activity is essentially 
a nonspecific side reaction of its biological function [13]. 
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The micromolar Km for ribosomes is indicative of the tight binding affinity that 
RTA has for its natural substrate. It is useful in structure-based inhibitor design to 
understand the chemical nature of that binding.  The heart of substrate binding is the 
accommodation of the target adenine base in a “specificity” pocket in the RTA active 
site.  The nature of this interaction was observed in a complex with formycin 
monophosphate (FMP), a non hydrolyzable analog of AMP [9]. Crystallographic studies 
of RTA showed that in the absence of substrate, the RTA specificity pocket was 
“closed”; that is, the side chain of Tyr 80 rotated to block its entrance [14].  However, in 
the presence of a substrate analog, RTA adopts an “open” conformation in which 
Tyrosine 80 moves to accommodate the substrate, forming a π-stacking network with the 
adenine base and Tyrosine 123 (Figure 1). In addition to the π-stacking interactions, the 
substrate forms six hydrogen bonds with the binding pocket, conferring specificity for the 
adenine base. Successful design of potent inhibitors of RTA is expected to require that 





Figure 2: Structure of RTA complexed with substrate analog, formycin 5’-
monophosphate (PDB ID: 1FMP): The binding of the AMP analog formycin 
5’ monophosphate to the active site of RTA is shown above. The aromatic 
ring analogous to the adenine base of the natural substrate is sandwiched 
between Tyrosine 80 and 123 (right), and makes six hydrogen bonds, shown 
as dashed black lines (left), within the active site. 
The active site of RTA can be described as having two binding pockets when it is 
in the open conformation: the primary adenine specificity pocket and a slightly larger 
secondary pocket. These two pockets are separated by the side chain of Tyrosine 80. The 
second pocket was proposed, based on model building, to accommodate a guanine base 
from the invariant GAGA ribosomal target sequence [9]; this has been confirmed by the 
X-ray structure of an RTA complex with a locked cyclic nucleotide [10]. The guanine 
base forms an aromatic stack with Tyrosine 80, and thereby forms an extended stack of 
Tyr 123, the adenine in the specificity pocket, Tyr 80 and the guanine base.  However, 
the binding of guanine appears to be weak as we have been unable to soak the free base, 
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nucleoside or nucleotide into that site.  Its observed binding in the cyclic tetranucleotide 
is speculated to be driven by the conformational rigidity of that ligand which reduces 
configurational entropy of binding. Our efforts to construct small dinucleotide substrate 
analogs that bind to both pockets have been unsuccessful, illustrating the importance of 




Chapter 3: Ricin Inhibitors 
3.1 – Ricin inhibitors show poor RTA inhibition. 
Recently, ricin inhibitors have been identified through classical high throughput 
screening strategies using large libraries of compounds to protect cultured cells from 
intoxication [24].  However, ricin intoxication is a complex process involving cell uptake, 
trafficking to the ER, release to the cytoplasm, and ribosome inactivation.  The cell based 
assay does not identify which process or protein [16] an anti-ricin compound is acting on. 
Another cell-based screen identified an anti-ricin compound that acts, not by inhibiting 
RTA action, but by disrupting cell trafficking [25]. Without a clear understanding of the 
macromolecular target being inhibited, it is difficult to rationally improve upon the initial 
high throughput hits. Of those inhibitors identified in the cell-based assay, only a small 
percentage showed anti-RTA activity in cell-free systems. Those compounds that did 
inhibit RTA were only weak inhibitors, and efforts to obtain a complex structure of these 
compounds with RTA have been fruitless. 
3.2 – Pteroic Acid as a lead compound for RTA inhibitor design 
To date, compounds that inhibit RTA action have been mainly discovered by 
virtual screening and structure-based design [27, 29, 30]. Such compounds have been 
identified using computer simulated docking of large virtual compound libraries to a 
model of the open form of RTA and confirming their anti-RTA activity using cell-free 
translation assays  [27, 28, 29]. Many of these were successfully soaked or co-crystallized 
with RTA, and their X-ray structures revealed binding to the adenine specificity pocket. 
The inhibitors that yielded complex structures had numerous structural similarities, the 
most important of which being an exocyclic amine that donates two hydrogen bonds to 
the backbone carbonyls of Valine 81 and Glycine 121. Another important characteristic is 
9 
 
aromaticity, which is necessary for the stacking interaction with the two tyrosine side 
chains.  
The first RTA inhibitor identified from virtual screening was pteroic acid, PTA, 
which had an apparent IC50 of 600 μM [29]. The crystal structure of the RTA-pteroic acid 
complex (Figure 2) reveals that the pterin group binds in the adenine specificity pocket, 
making six hydrogen bonds. Also, the benzoic acid moiety is in close proximity to the 
secondary pocket, and makes an additional hydrogen bond. Unfortunately, efforts to 
improve the inhibitory activity of pteroic acid by attaching pendants at the benzoic acid 
group were unsuccessful due to synthetic restrictions. 
 
Figure 3: The crystal structure of the complex of RTA with pteroic acid is shown 




Chapter 4: Design of Novel Pterin-based Inhibitors 
Although the pterins have limited solubility, their ability to interact with a number 
of specific groups in the RTA active site makes them an attractive drug design platform. 
Based on the structural data for pterin binding in the specificity pocket, it is apparent that 
synthetic extensions can be made from pterin at positions 6 and 7, which could, in 
principle, reach toward the second pocket on the enzyme surface; most naturally 
occurring pterins such as pteroic acid, neopterin, and folate are substituted at the 6 
position [31, 32, 33, 34].  
4.1 – 7-substituted pterins are more effective RTA inhibitors 
Synthetic chemists from Eric Anslyn’s lab made early efforts to derivatize at the 6 
and 7 positions via the addition of a carboxylic acid group. This was intended to enhance 
the solubility of the compounds in aqueous media, as well as adding an attachment point 
for nucleophiles, i.e. primary amines. Upon testing both 6 and 7 carboxy pterin (7CP) for 
RTA inhibition, the results overwhelmingly favored the 7 isomer. The apparent IC50 of 
7CP was 240 µM, a nearly 3-fold improvement over pteroic acid, while 6CP had no 
measureable inhibition [35, 36]. It was therefore decided that synthetic optimization of 
the pterins would proceed exclusively off of the 7CP platform. 
4.2 – Amino acids used as building blocks for 7CP derivatives 
Various 7CP derivatives were synthesized using simple primary amines to attach 
pendants via nucleophilic attack on the carboxyl group. This gave mixed results, most 
compounds being weaker inhibitors than the parent compound with the pendant often 
being too labile to be resolved in the complex structures. In an effort to cost-effectively 
create a diverse collection of longer and more complex pendants, a systematic approach 
11 
 
was adopted in which amino acids and short peptide chains were conjugated to 7CP. The 
resulting compounds bear long yet rotationally limited extensions with the potential to 
reach the secondary binding pocket of RTA and make some intermolecular contacts 
between the two pockets to reinforce the binding conformation of the ligand. All 
compounds presented were synthesized by Jeff Pruet (7CP) and Ryota Saito (RS-series) 




Chapter 5: Methods 
5.1 – Firefly Luciferase Assay 
RTA inhibition was measured using an in vitro translation assay. Firefly 
luciferase mRNA was translated in a cell free rabbit reticulocyte lysate system. The 
compounds to be tested were solubilized in 0.05 N KOH prior to their inclusion in the 
assay. The assay was run in the presence of BSA at concentrations in excess of that of 
RTA in order to neutralize compounds which non-specifically aggregate and sequester 
proteins, which is a common problem in assays like this one [37]. Prior to the start of the 
assay, the compounds are mixed with RTA and BSA and allowed to sit at room 
temperature for a 30 minute pre-incubation. Translation is initiated by the addition of 
rabbit reticulocyte lysate and translation mix (amino acids, RNasin ribonuclease inhibitor, 
luciferase mRNA). The reaction mixture is incubated at for 90 minutes at 30 °C, after 
which the reaction is quenched by freezing at -20 °C. After thawing at room temperature, 
the reaction mixtures are mixed with the Luciferase Substrate Reagent (Promega), and 
their luminescence measured on a Perkin Elmer Envision luminometer (Waltham MA). 
For each concentration of compound that is to be tested, a reaction is run both in 
the presence and absence of RTA. The translation inhibition due to RTA, independent of 
effects caused by the compound, is quantified by the difference in luminescence between 
the two reactions. This value divided by the control translation inhibition calculated for 
the reactions without any test compound to yield percent RTA activity. These values are 
plotted and fitted to a hyperbolic decay equation using least squares regression analysis to 
derive the IC50. 
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5.2 – Solution of complex structures 
RTA crystallizes in two space groups: monoclinic (P21) and tetragonal (P41212). 
Monoclinic crystals grow in 0.8% PEG 8000 75 mM Tris-HCl pH 8.9 and require 
seeding for nucleation. Tetragonal crystals grow in 1.2 M ammonium sulfate 100 mM 
sodium malonate pH 6.0 and nucleate spontaneously. After the 7CP structure was solved 
using the monoclinic crystal form, the tetragonal crystals were used for subsequent 
experiments because of their more consistent tolerance of changing conditions such as 
soaking pH and cryoprotection. All crystals were grown and stored at 4 °C. 
Compounds were soaked into RTA crystals by transferring the crystals into drops 
of mother liquor containing 1 mM of compound. Crystals were allowed to soak for no 
less than 24 hours prior to data collection. Data were collected with synchrotron radiation 
from beam line 5.0.2 of the Advanced Light Source (ALS) in Berkley, CA. Data sets 
were indexed, integrated, and merged using HKL2000 [38]. Phasing was done via 
molecular replacement using Molrep from the CCP4 software suite [39]. The search 
model used was a modified version of the RTA structure (PDB ID: 1RTC) in which TYR 
80 was replaced with alanine. This was a precautionary measure to avoid phasing errors 
due to the position of the tyrosine side chain in the closed form model overlapping with 
the position of the ligand occupying the active site. Following refinement using 
REFMAC5 [40] and model editing using COOT, compounds were modeled into the 
unoccupied electron density in the binding pocket. Restraints necessary for modeling and 
refinement of the compound coordinates were generated using the PRODRG server [41]. 





Table 1.  Data collection and refinement statistics for 7CP and single amino acid 
derivative complex structures. 
 7CP RS2-021-1 RS2-022-1 
Resolution range 
(Ã…) 
50  - 1.29 (1.31  - 
1.29) 
50  - 1.7 (1.73  - 
1.7) 
50  - 1.44 (1.46  - 
1.44) 
Space group P 1 21 1 P 41 21 2 P 41 21 2 
Unit cell 42.662 67.567 49.41 
90 112.78 90 
67.947 67.947 
140.783 90 90 90 
67.805 67.805 
140.813 90 90 90 
Total reflections 227142 520645 818515 
Unique reflections 61936 36849 59509 
Multiplicity 3.7 (3.6) 14.1 (14.3) 13.6 (10.9) 
Completeness (%) 95.31 (91.74) 99.75 (97.49) 98.94 (99.59) 
Mean I/sigma(I) 18.45 (3.46) 20.82 (3.27) 21.06 (2.84) 
Wilson B-factor 14.13 22.26 17.72 
R-sym 0.042 (0.276) 0.087 (0.766) 0.079 (0.844) 
R-factor 0.2069 (0.2281) 0.2132 (0.2403) 0.2051 (0.2731) 
R-free 0.2327 (0.2481) 0.2523 (0.2989) 0.2348 (0.2918) 
Number of atoms 2171 2327 2549 
  protein 2041 2078 2122 
  ligands 15 39 61 
  water 115 210 366 
Protein residues 258 263 263 
RMS(bonds) 0.028 0.022 0.043 
RMS(angles) 2.18 2.48 3.27 
Ramachandran 
favored (%) 
99 98 98 
Average B-factor 16.00 25.20 22.60 
  protein 15.70 24.90 20.50 
  solvent 20.10 29.00 33.60 




Table 2.  Data collection and refinement statistics for 7CP-dipeptide complex structures. 
 RS2-058-1 RS2-136-1 RS2-150-1 
Resolution range 
(Ã…) 
50  - 1.52 (1.55  - 
1.52) 
50  - 1.58 (1.61  - 
1.58) 
50  - 1.75 (1.78  - 
1.75) 
Space group P 41 21 2 P 41 21 2 P 41 21 2 
Unit cell 67.999 67.999 
140.692 90 90 90 
68.009 68.009 
141.023 90 90 90 
67.762 67.762 
140.657 90 90 90 
Total reflections 707566 667334 277750 
Unique reflections 51044 46156 31069 
Multiplicity 13.8 (13.3) 12.2 (3.9) 8.9 (9.0) 
Completeness 
(%) 
99.23 (99.82) 99.99 (100.00) 91.80 (99.34) 
Mean I/sigma(I) 19.09 (2.86) 22.39 (2.17) 15.11 (2.52) 
Wilson B-factor 18.84 19.21 21.28 
R-sym 0.098 (0) 0.098 (0) 0.087 (0) 
R-factor 0.2011 (0.2426) 0.2121 (0.2510) 0.2372 (0.3064) 
R-free 0.2304 (0.2949) 0.2391 (0.2952) 0.2679 (0.3519) 
Number of atoms 2510 2375 2237 
  protein 2083 2110 2117 
  ligands 30 26 39 
  water 397 239 115 
Protein residues 263 263 263 
RMS(bonds) 0.028 0.011 0.039 
RMS(angles) 2.19 1.38 1.99 
Ramachandran 
favored (%) 
98 98 98 
Ramachandran 
outliers (%) 
0.38 0.38 0.38 
Average B-factor 23.20 22.10 23.60 
  protein 21.10 20.90 23.30 
  solvent 34.50 29.90 28.00 
Statistics for the highest-resolution shell are shown in parentheses. 
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Table 3.  Data collection and refinement statistics for 7CP-tripeptide complex structures. 
 RS2-123-2 RS2-149-1 
Resolution range 
(Ã…) 
50  - 1.7 (1.73  - 
1.7) 
50  - 1.75 (1.78  - 
1.75) 
Space group P 41 21 2 P 41 21 2 
Unit cell 67.723 67.723 
140.592 90 90 90 
67.689 67.689 
140.72 90 90 90 
Total reflections 416685 464449 
Unique reflections 33719 31660 
Multiplicity 12.3 (12.4) 14.6 (14.9) 
Completeness 
(%) 
91.34 (99.39) 93.52 (90.03) 
Mean I/sigma(I) 12.07 (2.69) 18.75 (3.22) 
Wilson B-factor 24.76 23.72 
R-sym 0.091 (0) 0.096 (0) 
R-factor 0.2159 (0.2595) 0.2215 (0.2627) 
R-free 0.2584 (0.2982) 0.2589 (0.3358) 
Number of atoms 2347 2242 
  protein 2090 2078 
  ligands 65 78 
  water 192 86 
Protein residues 263 263 
RMS(bonds) 0.037 0.023 







Average B-factor 25.60 24.00 
  protein 24.30 23.70 
  solvent 34.20 24.70 




Chapter 6: Results 
6.1 – 7-carboxy pterin 
The compound, 7 – carboxy pterin (7CP), was tested in the luciferase assay in 
triplicate, and had an IC50 of 240 µM (Figure 4A). The crystal structure of 7CP in 
complex with RTA, solved in the P21 space group to a resolution of 1.29 Å, is shown in 
Figure 4B. As seen in previous structures of RTA in complex with pterins, the 2-amino 
group of the pterin ring donates one hydrogen bond each to the carbonyl oxygen atoms of 
Val81 and Gly121, and the 4-oxo and N5 atoms accept hydrogen bonds from Arg180. 
The tautomeric form of the pterin with a proton on N1 is favored so that N1 can donate a 
hydrogen bond to the carbonyl oxygen of Gly121 and N3 can accept a hydrogen bond 
from the amido N of Val81. An additional hydrogen bond, which was not seen in the 
previous 6-substituted pterins, is made between the amido N of Tyr123 and the carbonyl 
oxygen of the 7-carboxy group. This extra hydrogen bond is retained in all subsequent 
amide derivatives based on 7CP owes to the general increase in potency of this series of 







Figure 4: A. Dose response of 7-carboxy-pterin averaged from six repetitions of the 
firefly luciferase assay. The IC50 was calculated as 240 µM. B. Complex 
crystal structure of 7CP (yellow) and RTA (orange). The compound forms 7 
hydrogen bonds, shown as black dashed lines, with RTA. 
6.2 – Single amino acid derivatives 
The two single amino acid 7CP derivative compounds presented in this thesis are 
7CP-alanine (RS2-021-1) and 7CP-serine (RS2-022-1). Having an apparent IC50 value of 
350 µM, the alanine derivative shows a slight decrease in potency from its parent 
compound. The crystal structure, solved in the P41212 space group at a resolution of 1.7 
Å, shown in Figure 5B, shows that the alanine side chain makes only a minimal 
contribution to the binding affinity via a weak hydrophobic contact with the alpha carbon 
of Asn 209. The addition of two rotatable bonds and only a weak hydrophobic contact are 




Figure 5: A. Dose response of RS2-021-1 averaged from six repetitions of the firefly 
luciferase assay. The IC50 was calculated as 350 µM. B. Complex crystal 
structure of RS2-021-1 (yellow) and RTA (orange). The compound forms 
no hydrogen bonds outside the primary binding pocket, but does make a 
hydrophobic contact with Asn-209. 
The serine derivative RS2-022-1 showed a slight increase in potency over 7CP 
with an apparent IC50 of 175 µM. The crystal structure, which was solved in the P41212 
space group at a resolution of 1.44 Å, is shown in Figure 6B. The serine side chain’s 
hydroxyl group donates a hydrogen bond to the backbone carbonyl oxygen of Glu 208. 
The second pocket also appears to be occupied by another RS2-022-1 molecule, although 
the electron density was only enough to account for 50% occupancy. The tautomer of the 
pterin group of the second molecule with the proton on N3 is favored so that N1 and N8 
can both accept hydrogen bonds from the side chain amide group of Asn 78. 
Additionally, the exocyclic amine donates a hydrogen bond to the Asp 75 side chain, and 
the 4-oxo atom accepts a hydrogen bond from the backbone NH of Asp 96. The OH 
group from the serine pendant also accepts a hydrogen bond from the guanidinium group 
of Arg 258. Because of the 50% occupancy, Tyr 80 has two distinct positions in the 
presence and absence of the second ligand, its inward facing conformation lining up with 




Figure 6: A. Dose response of RS2-022-1 averaged from six repetitions of the firefly 
luciferase assay. The IC50 was calculated as 175 µM. B. Complex crystal 
structure of RS2-022-1 (yellow) and RTA (orange). The compound forms a 
hydrogen bond (black dashed lines) with Glu-208. A second molecule of 
RS2-022-1 (blue) binds in the secondary pocket, making five hydrogen 
bonds with RTA. 
6.3 – Dipeptide compounds 
The three dipeptide derivative presented here, 7CP-Gly-Phe (RS2-058-1), 7CP-
Gly-Tyr (RS2-136-1), and 7CP-Ser-Phe (RS2-150-1), are representative of early efforts 
to optimize the amino acid sequence of these inhibitors by varying the first and second 
amino acids independently. RS2-058-1, the first dipeptide tested had an apparent IC50 of 
20 µM, a more than ten-fold improvement over 7CP. From the structure in Figure 7B, 
which was solved in the P41212 space group at a resolution of 1.52 Å, a unique edge to 
face stacking interaction between the edge of the Trp 211 and the face of the 
phenylalanine pendant is observed. This interaction alone could account for the increased 
binding affinity because it is roughly equivalent to the strength of a hydrogen bond [42, 
43] and the water displaced for this interaction is energetically favorable since both 
structures are hydrophobic. Aromatic residues in the second position are expected to 




Figure 7: A. Dose response of RS2-058-1 averaged from six repetitions of the firefly 
luciferase assay. The IC50 was calculated as 20 µM. B. Complex crystal 
structure of RS2-058-1 (yellow) and RTA (orange). The phenyl group 
makes an edge-to-face stacking interaction (grey dashed lines) with Trp-
211. 
The 7CP-Gly-Tyr compound (RS2-136-1) had an IC50 of 15 µM, a slight 
improvement over the 7CP-Gly-Phe compound (RS2-058-1). As predicted, the crystal 
structure (Figure 8B), solved in the P41212 space group at a resolution of 1.58 Å, shows 
that this compound adopts an almost identical binding pose to RS2-058-1, with the 
aromatic tyrosine side chain in position for the edge to face stacking interaction with Trp 
211. Contrary to what was expected, the phenolic hydroxyl group on the tyrosine is not 
involved in any hydrogen bonding. Instead, it is likely that the increased binding affinity 
of this compound over the phenylalanine-containing one is due to the electron donating 
character of the hydroxyl group, which enhances the edge to face stacking interaction by 




Figure 8: A. Dose response of RS2-136-1 averaged from six repetitions of the firefly 
luciferase assay. The IC50 was calculated as 15 µM. B. Complex crystal 
structure of RS2-136-1 (yellow) and RTA (orange). The phenol group 
makes an edge-to-face stacking interaction (grey dashed lines) with Trp-
211. 
Substitution of the glycine residue for serine in the first position to yield 7CP-Ser-
Phe (RS2-150-1) led to a decrease in binding affinity with an apparent IC50 of 50 µM. 
The reason for this becomes quite apparent when looking at the crystal structure (Figure 
9B), which was solved in the P41212 space group at a resolution of 1.75 Å. The edge to 
face interaction seen in the previous two structures is lost. Instead, Tyr 80 rotates out to 
accept a hydrogen bond from the NH of the amide linking the serine and phenylalanine 
residues of the ligand. The positioning of Tyr 80 prevents the phenylalanine of RS2-150-
1 from orienting correctly for the interaction with Trp 211. There is another hydrogen 
bond made by the serine residue but it is donating to a malonate molecule rather than to a 
part of RTA. It is likely, however, that in normal conditions this hydrogen bond is 
donated to Glu 208 as was seen in the RS2-022-1 structure. From these results, we can 
see that the compactness and flexibility of glycine in the first position allows the second 




Figure 9: A. Dose response of RS2-150-1 averaged from six repetitions of the firefly 
luciferase assay. The IC50 was calculated as 50 µM. B. Complex crystal 
structure of RS2-150-1 (yellow) and RTA (orange). The compound forms 
two hydrogen bonds, shown as black dashed lines; one with Tyr-80 and the 
other with a malonate molecule (white). 
6.4 – Tripeptide compounds 
The first tripeptide compound tested, 7CP-Gly-Phe-Phe (RS2-123-2), was an 
extension of the potent inhibitor RS2-058-1 with another phenylalanine residue in the 
third position. What resulted was a moderate increase in binding affinity with RS2-123-2 
having an apparent IC50 of 15 µM. The crystal structure (Figure 10B) was solved in the 
P41212 space group at a resolution of 1.7 Å, and shows that the phenylalanine in the 
second position makes the edge to face interaction with Trp 211 as expected. The extra 
phenylalanine residue makes no additional interactions with the protein, but is instead 
aligned parallel to the other phenylalanine. The two phenylalanine residues make an 
intramolecular pi stacking interaction which could possibly contribute to the increased 




Figure 10: A. Dose response of RS2-123-2 averaged from six repetitions of the firefly 
luciferase assay. The IC50 was calculated as 15 µM. B. Complex crystal 
structure of RS2-123-2 (yellow) and RTA (orange). The two phenyl rings 
stack parallel with one another, while the first ring makes an edge-to-face 
stacking interaction (grey dashed lines) with Trp-211. 
A virtual drug screen of 7CP tripeptides predicted that 7CP-Ser-Gly-Trp (RS2-
149-1) would have the strongest binding affinity of the group. The resulting IC50 of this 
compound was 25 µM, making this a potent RTA inhibitor on par with RS2-058-1. The 
binding pose, particularly regarding the position of the tryptophan residue, is somewhat 
uncertain based on the ambiguous electron density at this position. As seen in the crystal 
structure shown in Figure 11B, which was solved in the P41212 space group at a 
resolution of 1.75 Å, the tryptophan of RS2-149-1 either makes a cation-pi interaction 
with Arg 258 and hydrophobic interactions with the residues in the surrounding surface, 
or makes the edge-to-face stacking interaction with Trp 211 while the carboxy terminus 
interacts with Arg 258. Additionally, the serine in the first position donates a hydrogen 
bond to the backbone carbonyl oxygen of Glu 208. This interaction is nearly identical to 
the one seen in the crystal structure of RS2-022-1, providing evidence that one should 





Figure 11: A. Dose response of RS2-149-1 averaged from six repetitions of the firefly 
luciferase assay. The IC50 was calculated as 25 µM. B. Complex crystal 
structure of RS2-149-1 (yellow) and RTA (orange) with Fo-Fc omit map 
(green) contoured at 2 sigma around the ligand. The compound forms a 
hydrogen bond, shown as black dashed lines, with Glu-208. The density for 
the indole ring of the compound suggests that multiple binding 
conformations exist: one in which the indole forms a cation-pi interaction 
with Arg-258 and makes hydrophobic contacts with the surface around this 
residue, and another in which the indole makes an edge-to-face stacking 
interaction with Trp-211 while the carboxylic acid forms an ionic/hydrogen 




Chapter 7: Discussion 
The application of structure-based drug design to the pterin-amino acid series of 
RTA inhibitors has provided a wealth of valuable information. The inhibitory data and 
complex structures for each of these compounds give some insight into a rough structure-
activity relationship. From the data for the series of dipeptide and tripeptide 7CP 
derivatives with aromatic amino acids in the second position, it is evident that the edge to 
face stacking interaction observed in these structures contributes greatly to activity. For 
all compounds that make this interaction, the IC50 was at least ten times lower than that of 
7CP. Of the compounds lacking this feature, none performed as well in the assay, 
although RS2-150-1 and RS2-149-1 came close with IC50 values of 50 µM and 25 µM 
respectively. In each of these structures, multiple ligand-receptor interactions were 
observed in the amino acid pendants which contributed to the increased binding affinity. 
7.1 – Ideal amino acid sequences for further extensions 
The consistency observed in the structures allows for predictions to be made 
regarding the binding pose and performance of future compounds based on the amino 
acid sequence of their pendants. For example, a serine in the first position will likely 
donate a hydrogen bond to Glu 208, and an aromatic second will probably make an edge 
to face pi stacking interaction with Trp 211. From the structure of RS2-150-1, however, 
we know that these two features are unable to be combined in the same molecule, 
meaning that glycine must be used in the first position in order for the aromatic residue in 
the send position to make its interaction. We also know now that the ideal aromatic 
amino acid for this interaction is tyrosine.  
Due to the failure of any of the tripeptide compounds to extend into the second 
pocket, it is apparent that at least a four amino acid chain would be needed for this task. 
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From the limited data available for tripeptides, it appears as though the third amino acid 
position is of little importance if the second one is aromatic. This is due to the fact that 
the third amino acid is in an isolated position too far away from the protein surfaces to 
make any useful contacts. Knowing this and the ideal first two amino acids, the logical 
starting point for designing four amino acid derivatives of 7CP would begin with the 
sequence Gly-Tyr-Gly with an aromatic residue such as tryptophan in the fourth position 
which could potentially make a stacking interaction with Tyr 80 in the second pocket. 
The glycine in the third position, similar in role to the one in the first position, could 
provide the flexibility needed for the aromatic residue in the next position to extend into 
the second pocket.  
Another route worth exploring would be 3-4 amino acid derivatives with serine at 
the first two positions. There are several potential hydrogen bond donors and acceptors in 
the vicinity that could form one or more contacts with the second serine, which could 
possibly make up for the lack of an edge to face stacking interaction provided by 
aromatic amino acids. Depending on how the peptide chain orients, an aromatic amino 
acid in the third position or one in the fourth preceded by a glycine could potentially 
stack in the second pocket. 
7.2 – Occupation of the second pocket 
The crystal structure for RS2-022-1 in complex with RTA had a unique feature 
that has never been seen before in RTA complex structures. The pterin appears in both 
the primary and secondary binding pocket, providing valuable insight into how pendants 
should be designed to promote binding in the second pocket. From the structure, it 
appears that the two molecules are bound close enough together to be connected together 
by a short linker such as ethylene diamine. It would be worthwhile to have such a 
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symmetric bis-7CP-Ser compound synthesized to have analyzed to see if it is indeed 
possible to have both pockets occupied by a single bidentate ligand.  
Pterins have notorious solubility problems, so it is likely that adding a second 
pterin ring to the inhibitor platform will be problematic. Fortunately, the binding in the 
second pocket is not as specific to the pterin as the primary pocket is as only 4 hydrogen 
bonds are made. From the structure, we know that N1, N8, and O4 act as hydrogen bond 
acceptors and the exocyclic amine donates one hydrogen bond. The other two hetero 
atoms of the pterin do not appear to be needed for binding specificity. This in in 
agreement with how the guanine base binds the second pocket in the published 
tetranucleotide substrate analog structure [10], as all of the same amino acids are 
involved in hydrogen bonding. Also, the interaction with Arg 258 appears to be an 
important anchor, as this residue makes an ion pair with the phosphate in the 
tetranucleotide structure. In light of these similarities, an obvious alternative to the pterin 
ring in the second pocket would be guanine substituted at the 8 position, which would be 
analogous to the 7 position on the pterin. 
7.3 – Peptide alternatives 
While this approach of using peptide pendants has yielded potent RTA inhibitors, 
they are unlikely to be effective in an in vivo system due to degradation by proteases. It is 
therefore necessary, once ideal peptide pendants have been identified, to eliminate 
peptide bonds from the structure while maintaining the important features of the peptide 
inhibitor. There are many isosteres for peptides but they often expand or restrict the 
flexibility of the parent structure, so it is unpredictable how these potential analogs will 
perform. An example of such analogs is a series of RTA inhibitors that are based on the 
triazole linker derived from copper catalyzed click chemistry [44]. Compounds bearing 
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pendants in which the triazole is followed by an aromatic group perform well in the 
luciferase assay and bind in a similar fashion to the glycine aromatic dipeptide 
compounds. Despite making the same interactions as these dipeptides, the triazoles lose 
some flexibility making them too conformationally restrained to position the aromatic 
group at the ideal distance and angle for the edge to face interaction with Trp 211, so 
their inhibition of RTA is not as strong. Triazoles and other potential linkers such as 
hydrazides, sulfonamides, and ureas need to be explored with the goal of mirroring the 
features of the peptide pendants. Although these peptide based RTA inhibitors are 
unlikely to become effective drugs, they will provide a wealth of structural information to 
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